title: Visual performance in giant cell arteritis (temporal arteritis) after 1 year of therapy.
abstract: OBJECTIVE
  To determine if patients with giant cell arteritis (GCA) treated with corticosteroids develop delayed visual loss or drug related ocular complications.
  
  
  METHODS
  In a multicentre prospective study patients with GCA (using precise diagnostic criteria) had ophthalmic evaluations at predetermined intervals up to 1 year. The dose of corticosteroid was determined by treating physicians, often outside the study, with the daily dose reduced to the equivalent of 30-40 mg of prednisone within 5 weeks. Subsequently, treatment guidelines suggested that the dose be reduced as tolerated or the patient was withdrawn from steroids in a period not less than 6 months.
  
  
  RESULTS
  At presentation, of the 22 patients enrolled, seven patients had nine eyes with ischaemic injury. Four eyes had improved visual acuity by two lines or more within 1 month of starting corticosteroids. No patients developed late visual loss as the steroid dose was reduced. At 1 year the visual acuity, contrast sensitivity, colour vision, and threshold perimetry were not significantly different from the 4-5 week determinations. At 1 year, there were no significant cataractous or glaucomatous changes. At 2 months, there was no difference in systemic complications between patients who received conventional dose (60-80 mg per day) or very high doses (200-1000 mg per day) of corticosteroids at the start or early in the course.
  
  
  CONCLUSIONS
  Patients with GCA related visual loss can improve with treatment. Corticosteroids with starting doses of 60-1000 mg per day, with reduction to daily doses of 40-50 mg per day given for 4-6 weeks, and gradual dose reduction thereafter, as clinically permitted, did not result in delayed visual loss. There were no significant drug related ophthalmic complications.
authors.affiliation: INN at Beth Israel Medical Center, New York, NY 10128, USA.
authors.forename: M J
authors.initials: MJ
authors.lastname: Kupersmith
authors.forename: R
authors.initials: R
authors.lastname: Langer
authors.forename: H
authors.initials: H
authors.lastname: Mitnick
authors.forename: R
authors.initials: R
authors.lastname: Spiera
authors.forename: H
authors.initials: H
authors.lastname: Spiera
authors.forename: M
authors.initials: M
authors.lastname: Richmond
authors.forename: S
authors.initials: S
authors.lastname: Paget
mesh_terms: D000305:Adrenal Cortex Hormones / Q000627:therapeutic use*; D000368:Aged; D003117:Color Vision Defects / Q000209:etiology; D015350:Contrast Sensitivity / Q000502:physiology; D005260:Female; D005500:Follow-Up Studies; D013700:Giant Cell Arteritis / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use; D008775:Methylprednisolone / Q000627:therapeutic use; D011239:Prednisolone / Q000627:therapeutic use; D011446:Prospective Studies; D012684:Sensory Thresholds / Q000502:physiology; D014786:Vision Disorders / Q000188:drug therapy* / Q000503:physiopathology; D014792:Visual Acuity / Q000502:physiology
chemical_list: D000305:Adrenal Cortex Hormones; D011239:Prednisolone; D008775:Methylprednisolone; D008727:Methotrexate